Glenmark Pharmaceuticals to study potential COVID-19 drug combination

by | May 26, 2020 | COVID - 19 | 0 comments

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Reuters

Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs – favipiravir and umifenovir – as a potential COVID-19 treatment.

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.

Click Here For Original Source Of Article

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Facebook